Product Description: Lucicebtide acetate is the acetate salt form of Lucicebtide (HY-P10376). Lucicebtide acetate is a selective antagonist for CCAAT/enhancer binding protein β (C/EBPβ). Lucicebtide acetate binds to the leucine zipper domain of C/EBPβ, prevents its dimerization, and ubiquitin-dependently degrades C/EBPβ. Lucicebtide acetate arrests cell cycle at G0/G1 phase. Lucicebtide acetate exhibits cytotoxicity in cancer cells. Lucicebtide acetate exhibits good pharmacokinetic characters and inhibits tumor growth in mouse model[1].
Applications: Cancer-programmed cell death
Formula: C208H345N69O55S.xC2H4O2
References: [1]Darvishi E, et al., Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β. Mol Cancer Ther. 2022 Nov 3;21(11):1632-1644.
Molecular Weight: 4724.46 (free base)
Compound Purity: 98.28
Research Area: Cancer
Target: Others
English
Deutsch
